<DOC>
	<DOC>NCT01204086</DOC>
	<brief_summary>The purpose of this study is to establish the clinical effectiveness of antidepressants by pharmacogenomic approach, and to determine the levels of inflammatory factors between the baseline and the end point of the study in Taiwanese major depressive disorder (MDD) patients.</brief_summary>
	<brief_title>Pharmacogenomics Studies of Antidepressants</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Age: 1665 years old Signed informed consent by patient or legal representative Hamilton Rating Scale for Depression (HDRS) scores â‰¥ 16 A diagnosis of MDD according to DSMIV criteria made by a specialist in psychiatry monoamine oxidase inhibitor or antidepressant treatment within two weeks prior to entering the study A DSMIV diagnosis of substance abuse within the past three months An organic mental disease, mental retardation or dementia A serious surgical condition or physical illness Patients who were pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Antidepressants</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>venlafaxine</keyword>
	<keyword>fluoxetine</keyword>
</DOC>